13.30Open13.30Pre Close0 Volume1 Open Interest63.00Strike Price0.00Turnover475.29%IV-2.30%PremiumNov 29, 2024Expiry Date15.10Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9245Delta0.0115Gamma5.02Leverage Ratio-2.1282Theta0.0006Rho4.64Eff Leverage0.0037Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet